June 2018

New Product - Bavencio

Avelumab (rch) (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab removes the suppressive effects of PD-L1 on cytotoxic CD8⁺ T-cells, resulting in the restoration of anti-tumour T-cell responses. Bavencio is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma. This indication is approved based on tumour response rate, duration of response in a single arm study. Bavencio concentrated solution for intravenous infusion (200 mg/10 mL) is available in a pack size of 1 vial.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au